Product nameAnti-PAR4 antibody [EPR3991]
See all PAR4 primary antibodies
DescriptionRabbit monoclonal [EPR3991] to PAR4
Tested applicationsSuitable for: WB, IPmore details
Unsuitable for: Flow Cyt,ICC or IHC-P
Species reactivityReacts with: Mouse, Human
Synthetic peptide within Human PAR4 aa 1-100 (N terminal). The exact sequence is proprietary.
- LNCap, Jurkat, A549 and HeLa cell lysates
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol, 9.85% Tris glycine, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab92590 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
WB: 1/10000 - 1/50000. Predicted molecular weight: 37 kDa.
Is unsuitable for Flow Cyt, ICC or IHC-P.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionPro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down-regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by itself. May be directly involved in regulating the amyloid precursor protein (APP) cleavage activity of BACE1.
Tissue specificityWidely expressed. Expression is elevated in various neurodegenerative diseases such as amyotrophic lateral sclerosis, Alzheimer, Parkinson and Huntington diseases and stroke. Down-regulated in several cancers.
DomainThe leucine-zipper domain is not essential for apoptosis, but is required for sensitization of cells to exogenous apoptotic insults and for interaction with its partners.
The SAC domain is a death-inducing domain selective for apoptosis induction in cancer cells. This domain is essential for nuclear entry, Fas activation, inhibition of NF-kappa-B activity and induction of apoptosis in cancer cells.
modificationsPreferentially phosphorylated at the Thr-163 by PKC in cancer cells.
Cellular localizationCytoplasm. Nucleus. Mainly cytoplasmic in absence of apoptosis signal and in normal cells. Nuclear in most cancer cell lines. Nuclear entry seems to be essential but not sufficient for apoptosis (By similarity). Nuclear localization includes nucleoplasm and PML nuclear bodies.
- Information by UniProt
- 2310001G03Rik antibody
- PAR 4 antibody
- PAR-4 antibody
All lanes : Anti-PAR4 antibody [EPR3991] (ab92590) at 1/10000 dilution
Lane 1 : LNCap cell lysate
Lane 2 : Jurkat cell lysate
Lane 3 : A549 cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 37 kDa
ab92590 at 1/40 immunoprecipitating PAR4 in Jurkat (human T cell leukemia T lymphocyte) whole cell lysate.
Lane 1 (+): ab92590 + Jurkat whole cell lysate
Lane 2 (-): PBS instead of ab92590 in Jurkat whole cell lysate
For western blotting, ab92590 was at 1/1000 dilution followed by Goat Anti-Rabbit IgG, (HRP), specific to the non-reduced form of IgG as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
ab92590 has not yet been referenced specifically in any publications.